Abstract: This invention encompasses compounds of the formula wherein Ar represents a mono-, di- or trisubstituted aryl group where at least one position on Ar ortho to the point of attachment to the pyrazole ring is substituted; and R1 represents lower alkyl; R2 is hydrogen or lower alkyl; and R3 and R4 independently represent organic and inorganic substituents, which compounds are highly selective partial agonists or antagonists at human CRF1 receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.

Abstract: The invention relates to novel substituted phenyluraciles of the general formula (I) in which m, n, Q and R1-7 are each as defined in the description, and to processes for their preparation and to their use as herbicides.

Abstract: A method for the production of melamine from urea via a high-pressure non-catalytic process in which molten urea is reacted to produce melamine, carbon dioxide, and ammonia, the by-product gases are separated from the melamine melt, and the melamine melt is treated with ammonia in a liquid-filled column to remove dissolved carbon dioxide, the treated melamine melt being solidified to produce high-purity melamine. In the liquid-filled column, or bubble column, the melamine melt is treated with between 0.02 and 3 tons of ammonia per ton of melamine, the bubble column being operated at a pressure of between 1 and 40 MPa and at a temperature between the melting point of melamine at prevailing pressure and 450° C., with the residence time of the melamine melt in the bubble column being between 1 minute and 10 hours.

Abstract: The present invention relates to novel pyrimidine derivatives and pharmaceutically acceptable non-toxic salts thereof which possess an excellent inhibitory activity against gastric acid secretion, a pharmaceutical composition containing the same as an active ingredient, and a process for the preparation thereof.

Abstract: Triazinoindole derivatives are useful in the prophylaxis and treatment of pestivirus infections and diseases associated with pestivirus infections.

Abstract: A compound selected from the group consisting of all possible isomers or racemates of a compound of the formula wherein the various substituents are as defined in the specification and its non-toxic, pharmaceutically acceptable salts with acids or bases having anti-anoxic, anti-ischemic and neuronal protective anti-depressant activities.

Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2 and Ar are as defined herein.

Abstract: The invention relates to novel compounds of formula I: wherein R1 through R5, A, X and Z have the meaning set forth in the description.

Abstract: The present invention relates to new positive allosteric AMPA receptor modulators of general formula (I) wherein R1, R2 R3, R4, R5 and R6 may have the meanings indicated in the specification and claims, processes for preparing them and their use as pharmaceutical compositions.

Abstract: The invention relates to a method for the preparation of 4,6-dichloropyrimidine by reacting 4-chloro-6-methoxypyrimidine with at least one sulphur-containing chlorinating agent selected from the group consisting of SCl2, SOCl2, and SO2Cl2 in the presence of at least one phosphorus compound having the formula R3P═Yn  (1), in which R represents C1-C10-alkyl or C6-C10-aryl, each of which may optionally be substituted by up to five identical or different substituents selected from the group consisting of fluorine, chlorine, bromine, C1-C4-alkyl, and C1-C4-alkoxy, Y represents oxygen or sulphur, and n represents zero or 1.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1 through R3 are as defined in the specification.

Abstract: The present invention is to provide a novel 5-iodo-4-phenethylaminopyrimidine derivative represented by the following formula (1): wherein R1 represents a halogen atom, a C2-4 acyloxy group or a hydroxyl group; R2 represents a hydrogen atom, a halogen atom, a C1-4 alkyl group, a C1-4 haloalkyl group, a C1-4 alkoxy group or a C1-4 haloalkoxy group; n is an integer of 1 to 3; and * represents an asymmetric carbon atom, useful as pesticides, a synthetic intermediate thereof and processes for producing these compounds, and pesticides containing the 5-iodo-4-phenethylaminopyrimidine derivative(s).

Abstract: The compounds of formula (I) wherein R1 has the significance as given in the description, are inhibitors of endothelin receptors and can therefore be used for the treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction.

Abstract: N-(Triazoloazinyl)thiophenesulfonamide compounds were prepared from appropriately substituted 2-amino[1,2,4]triazolo[1,5-c]pyrimidine, 2-amino[1,2,4]triazolo[1,5-a]pyrimidine and 2-amino[1,2,4]triazolo[1,5-a]pyridine compounds and appropriately substituted thiophenesulfonyl chloride compounds. The compounds were found to be useful as herbicides.

Abstract: Process for the industrial synthesis of (3aS)-5,5-dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine of formula (I): by enantioselective catalytic hydrogenation of 5,5-dioxo-2,3-dihydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine.

Abstract: A process for the production of a compound of formula (I) wherein R1 is hydrogen or C1-C4-alkyl; R2 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkinyl, C3-C6-cycloalkyl or a radical —CH2B; A is selected from the group consisiting of 2-chloropyrid-5-yl, tetrahydrofuran-3 -yl, 5-methyl-tetrahydrofuran-3-yl or 2-chlorothiazol-5-yl; and B is phenyl, 3-pyridyl or thiazolyl, which are optionally substituted by one to three substituents selected from the group consisting of C1-C3-alkyl, C1-C3-halogenalkyl, cyclopropyl, halogencyclopropyl, C2-C3-alkenyl, C2-C3-alkinyl, C1-C3-alkoxy, C2-C3-halogenalkenyl, C2-C3-halogenalkinyl, C1-C3-halogenalkoxy, C1-C3-alkylthio, C1-C3-halogenalkylthio, allyloxy, propargyloxy, allylthio, propargylthio, halogenallyloxy, halogenallylthio, halogen, cyano or nitro; and optionally the possible E/Z isomers, E/Z isomeric mixtures and/or tautomers thereof, respectively in free form or in salt form; characterised in that a compound of formula (II)

Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2 and Ar are as defined herein.

Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, N02, amino, and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 a

Abstract: The present invention describes novel pyrazolo[1,5-a]triazines of formula: wherein R3 is an alkyl, alkenyl, alkynyl, or cycloalkyl group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.